Alendronate reduces the excretion of risk factors for calcium phosphate stone formation in postmenopausal women with osteoporosis.

@article{Yasui2009AlendronateRT,
  title={Alendronate reduces the excretion of risk factors for calcium phosphate stone formation in postmenopausal women with osteoporosis.},
  author={Takahiro Yasui and Yasunori Itoh and Atsushi Okada and Shuzo Hamamoto and Masahito Hirose and Takahiro Kobayashi and Keiichi Tozawa and Kenjiro Kohri},
  journal={Urologia internationalis},
  year={2009},
  volume={83 2},
  pages={226-9}
}
OBJECTIVE Osteoporosis is associated with the pathogenesis and risk of urolithiasis, which is higher among postmenopausal women (as opposed to premenopausal). Bisphosphonates potently inhibit bone resorption, and are used in the management of bone disease. We investigated the ability of a bisphosphonate to prevent calcium stone formation. METHODS We studied 12 postmenopausal women (63.8 +/- 7.3 years) who were not receiving osteoporosis therapy, and had stones comprised of calcium phosphate… CONTINUE READING

Similar Papers

Loading similar papers…